Tech Company Financing Transactions
Constantiam Biosciences Funding Round
On 9/9/2024, Constantiam Biosciences secured $2.1 million in funding from National Human Genome Research Institute Home | NHGRI.
Transaction Overview
Company Name
Announced On
9/9/2024
Transaction Type
Debt
Amount
$2,050,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the amount to support the research and development of its statistical analysis platform, Varify�, which focuses on reclassifying variants of uncertain significance (VUS) at scale by leveraging Multiplexed Assays of Variant Effect (MAVEs).
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
6306 Grand Summit Court
Katy, TX 77494
USA
Katy, TX 77494
USA
Phone
Undisclosed
Website
Email Address
Overview
Our mission is to accelerate the development of life-saving precision diagnostics and therapeutics. We are dedicated to advancing healthcare by providing innovative solutions that enhance the accuracy and efficiency of genetic testing and drug discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nicholas Schafer
Chief Scientific Officer
Daniel Goldman
Co-Founder
Norman Ong
Browse more venture capital transactions:
Prev: 9/9/2024: CardiaTec venture capital transaction
Next: 9/9/2024: MirrorWeb venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs